Related Experiment Video
Updated: Jul 10, 2025
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
The Effect of Rho Kinase Inhibitors on In Vitro Human Orbital Preadipocytes
David Yoo1, Meredith Horacek1, Min Kyung Chae2
1Department of Ophthalmology, Loyola University Medical Center, Maywood, Illinois, U.S.A.
Purpose:
To identify the effects of Rho Kinase (ROCK) inhibitor medications on human orbital adipogenesis, fibroblast proliferation, and fibrosis.
Methods:
Orbital adipose tissue was obtained from patients with Graves' ophthalmopathy (GO) as well as controls (non-GO or normal) after informed consent was done. These tissue samples were cultured and adipogenesis was initiated. Levels of Rho Kinase as well as cellular mediators of orbital inflammation and fibrosis. The same cultures and measurements were then repeated with the use of a ROCK inhibitor (KD025-ROCK2) to assess for changes in adipogenesis as well as markers associated with inflammation and fibrosis.
Results:
Rho Kinase levels in GO tissue were more highly expressed than in controls. These levels were suppressed with the use of the ROCK inhibitor KD025. There was a dose-dependent reduction in differentiation of orbital adipocytes with the use of KD025. KD025 reduced the levels of fibrosis-related gene expression. Finally, there was a significant reduction of transforming growth factor beta mediated phosphorylation signaling pathways in the KD025-treated GO tissue.
Conclusion:
This study shows that the ROCK inhibitor, KD025, helps to reduce the expression of ROCK in GO tissue along with reducing orbital adipocyte differentiation as well as cell mediators involved in fibrosis that occurs in GO.
Insights
The Rho Kinase (ROCK) inhibitor KD025 reduces ROCK expression, orbital adipocyte differentiation, and fibrosis markers in Graves' ophthalmopathy (GO) tissue, offering a potential therapeutic approach for GO.
Area of Science:
- Ophthalmology
- Endocrinology
- Cell Biology
Background:
- Graves' ophthalmopathy (GO) is characterized by orbital inflammation, fibrosis, and adipogenesis.
- Rho Kinase (ROCK) signaling pathways are implicated in the pathogenesis of GO.
Purpose of the Study:
- To investigate the therapeutic potential of a ROCK inhibitor (KD025) in modulating human orbital adipogenesis, fibroblast proliferation, and fibrosis.
- To assess the impact of KD025 on ROCK expression and downstream signaling in GO orbital tissues.
Main Methods:
- Orbital adipose tissue was obtained from GO patients and controls.
- Adipogenesis was induced in cultured orbital tissues.
- ROCK expression, adipocyte differentiation, and fibrosis markers were measured.
- Tissues were treated with KD025 to evaluate its effects on these processes.
Main Results:
- ROCK expression was elevated in GO tissues compared to controls.
- KD025 treatment dose-dependently reduced orbital adipocyte differentiation.
- KD025 suppressed fibrosis-related gene expression.
- KD025 significantly reduced transforming growth factor beta-mediated signaling.
Conclusions:
- The ROCK inhibitor KD025 effectively reduces ROCK expression in GO orbital tissue.
- KD025 demonstrates potential in mitigating orbital adipocyte differentiation and fibrosis associated with GO.
More Related Videos
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
10:28Isolation, Expansion, and Adipogenic Induction of CD34+CD31+ Endothelial Cells from Human Omental and Subcutaneous Adipose Tissue
Published on: July 17, 2018
